Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT05006196

Contrast-Free Magnetic Resonance Imaging for Breast Disease

Contrast-Free Magnetic Resonance Imaging for Breast Disease — Active Not Recruiting • Oncology • NCT05006196.

📅 20 May 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT05006196
Start
2021-07-06
Completion
2026-12-31
ClinicaliQ Trial Snapshot
  • Contrast-Free Magnetic Resonance Imaging for Breast Disease — Active Not Recruiting • Oncology • NCT05006196.
  • MRI without contrast dye can accurately diagnose breast cancer in women at risk or with suspected disease.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Prospective, observational cohort study looking at patients either at risk of breast cancer or have clinically suspected breast to assess the diagnostic performance of quantitative, non-contrast MRI. Conditions: Breast Cancer, Breast Diseases Interventions: Outpatient MRI Lead Sponsor: Perspectum Planned Enrollment: 1030 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Breast cancer checks missing most women under 50 who are at risk, says study
Oncology · BBC Health · 04 Aug 2026
Current NHS breast screening programmes fail to identify approximately 95% of women under 50 at higher genetic or familial risk of breast…
View brief →
Clinical Brief
Lucy Davis urges women to check their breasts for cancer – here’s how
Oncology · BBC Health · 12 Aug 2026
Breast cancer can present as subtle findings—a hard spot rather than a discrete lump—emphasising the importance of thorough self-examination and patient awareness…
View brief →
Clinical Brief
Young women now have ‘close to zero’ risk of cervical cancer death after HPV jab
Oncology · BBC Health · 18 Jun 2026
The HPV vaccination programme introduced in 2008 has dramatically reduced cervical cancer mortality in vaccinated cohorts, with young women now facing near-zero…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
Oncology · 18 Jun 2026
Imlunestrant evaluation was terminated – NICE did not complete appraisal of imlunestrant for oestrogen receptor-positive HER2-negative advanced breast cancer; clinicians should refer…
View guideline →
Clinical Brief
Risk of cervical cancer death before 30 ‘close to zero’ after HPV vaccine
Oncology · BBC Health · 18 Jun 2026
Key Takeaways for Clinical Practice The HPV vaccination programme introduced in UK schools in 2008 has demonstrated significant real-world effectiveness, with cervical…
View brief →